Skinny, Inc. Part 1: the Canadian connection to Ozempic
The DecibelPlay episode
Show notes
Dr. Daniel Drucker’s research helped pave the way for Ozempic, the blockbuster GLP-1 class drug. The endocrinologist has been researching the effects on Ozempic’s active ingredient semaglutide in the body for decades.Today he’ll show us around his lab and explain how a stout lizard kept in a freezer helped unlock the science behind a drug taken by more than a million Canadians.
Then, health reporter Kelly Grant tells us about rising obesity rates in Canada, and we’ll hear from a doctor who prescribes GLP-1s— and a patient who takes them.
After this episode was published, Dr. Stephen Glazer let The Globe know that he misstated the ratio of fat to muscle loss during a typical weight loss experience. The typical ratio is around two-thirds fat loss and one-third muscle loss.
This is part of a three-part series. The next episode is next Monday, March 2nd.
You can contact the National Eating Disorders Information Centre at their toll-free hotline at 1-866-NEDIC-20 or visit their website.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
